Protocol for EpiCom: A phase 3b/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).

Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ

History

Local uptake of (14)C-

Protocol for EpiCom: A

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Protocol for EpiCom: A phase 3b/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).

van Eeghen AM, Thiele EA, Amin S, Samanta D, Jansen AC, Stevens J, Moore-Ramdin L, de Vries PJ. Protocol for EpiCom: A phase 3b/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). PLoS One. 2025; 20(6):e0324648.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Anticonvulsants
Cannabidiol
Child
Child, Preschool
Clinical Trials, Phase III as Topic
Female
Humans
Infant
Male
Mental Disorders
Middle Aged
Quality of Life
Seizures
Treatment Outcome
Tuberous Sclerosis
Young Adult

authors with profiles

Debopam Samanta